MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
MapLight’s clinical plans include FDA discussions on Phase 3 programs in schizophrenia and irritability associated with autism.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MapLight Therapeutics (MPLT) celebrated co-founder Karl Deisseroth’s receipt of the 2026 Nobel Prize in Physiology or Medicine for discoveries concerning optogenetics.
Deisseroth, a Scientific Advisory Board member, shares the award with Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics, tools for studying nerve-cell activity. His work inspired MapLight’s founding in 2018.
The Phase 2 ZEPHYR study of ML-007C-MA met its primary endpoint, showing statistically significant and clinically meaningful improvement in schizophrenia symptoms. MapLight intends to meet with the FDA and subsequently initiate Phase 3. It also intends to meet with the FDA to discuss a planned Phase 3 program in irritability associated with autism following Phase 2 IRIS.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointML-007C-MA’s Phase 2 ZEPHYR primary endpoint was met, showing statistically significant and clinically meaningful schizophrenia symptom improvement.
- Moderate point. Forward-looking: it has not happened yet and may not happen.MapLight intends to hold an FDA End-of-Phase 2 meeting and subsequently initiate Phase 3 in schizophrenia.
- Minor point. Forward-looking: it has not happened yet and may not happen.MapLight intends to discuss a planned Phase 3 program in irritability associated with autism with the FDA.
Negative
- None.
Historical Context
-
Phase 2 ZEPHYR met its primary endpoint with statistically significant symptom improvement versus placebo.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
optogenetics technical
light-gated ion channels technical
primary endpoint medical
end-of-phase 2 (eop2) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Award honors foundational discoveries in optogenetics and circuit mapping
These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery
SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogenetics.
The Nobel Assembly recognized optogenetics for transforming scientists’ ability to study how nerve cells shape memories, feelings and behaviors in the living brain, laying the foundation for a new era in neuroscience. Over the past two decades, optogenetics has fundamentally advanced the understanding of the biological basis of behavior, cognition and neuropsychiatric disease.
Dr. Deisseroth’s academic breakthroughs enabled scientists to investigate causal relationships between specific neural circuits and behavior and inspired the founding of MapLight in 2018. MapLight translates insights from circuit neuroscience into a precision approach to drug discovery, using optogenetics and related tools to identify specific cell types and molecular targets linked to psychiatric and neurodevelopmental symptoms. The Company then develops oral small-molecule candidates designed to modulate disease-relevant circuit activity and provide potential therapeutic relief.
This approach underpins the translation of circuit biology into a diverse pipeline of early- and clinical-stage product candidates. The Phase 2 ZEPHYR study of ML-007C-MA, which evolved from optogenetic and other preclinical work at MapLight, recently met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in schizophrenia symptoms. Based on these results, MapLight announced its intention to engage with the FDA in an End-of-Phase 2 (EOP2) meeting and subsequently initiate a Phase 3 study in schizophrenia. Similarly, preclinical work leveraging optogenetics in models of autism informed the design and conduct of the Phase 2 IRIS study. Based on these results, MapLight announced its intention to engage with the FDA in an EOP2 meeting to discuss a planned Phase 3 program in irritability associated with autism.
“Optogenetics began as a way to ask a basic question: how does electrical activity in specific cells give rise to human behavior and emotion?” said Dr. Deisseroth. “Neuroscience has long needed a better understanding of the functional biology of neural circuits and the relationship between circuit dysfunction and disease. I am deeply grateful to the institutions, trainees, and colleagues that have enabled and supported my work over the years, and to Peter Hegemann and Georg Nagel for their foundational contributions. As a practicing psychiatrist, seeing these basic biological discoveries move from the lab into human clinical trials is the ultimate realization of this work.”
“On behalf of everyone at MapLight, congratulations to Karl on this monumental achievement,” said Christopher Kroeger, M.D., Chief Executive Officer of MapLight. “The Nobel recognition of Karl’s academic work is a triumph for basic science and underscores the transformative impact of understanding the brain at the circuit level. Karl’s Nobel work inspired MapLight’s founding premise: that understanding the causal relationship between neural circuits and behavior can enable a more precise approach to developing medicines for complex CNS disorders. We are incredibly proud to celebrate this extraordinary honor with Karl and to continue advancing the mission that his work inspired.”
Additional information about the 2026 Nobel Prize in Physiology or Medicine and the discoveries recognized by the Nobel Assembly is available in its official announcement.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
For more information, please visit www.maplightrx.com.
For investor inquiries: investors@maplightrx.com
For media inquiries: media@maplightrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.